JP2023551877A5 - - Google Patents

Info

Publication number
JP2023551877A5
JP2023551877A5 JP2023533310A JP2023533310A JP2023551877A5 JP 2023551877 A5 JP2023551877 A5 JP 2023551877A5 JP 2023533310 A JP2023533310 A JP 2023533310A JP 2023533310 A JP2023533310 A JP 2023533310A JP 2023551877 A5 JP2023551877 A5 JP 2023551877A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
cells
composition according
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551877A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/133598 external-priority patent/WO2022116086A1/en
Application filed filed Critical
Publication of JP2023551877A publication Critical patent/JP2023551877A/ja
Publication of JP2023551877A5 publication Critical patent/JP2023551877A5/ja
Pending legal-status Critical Current

Links

JP2023533310A 2020-12-03 2021-12-03 Bcmaを標的とする、多発性骨髄腫のためのcar-t細胞療法 Pending JP2023551877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/133598 2020-12-03
PCT/CN2020/133598 WO2022116086A1 (en) 2020-12-03 2020-12-03 Bcma-targeted car-t cell therapy for multiple myeloma
PCT/CN2021/135295 WO2022117068A1 (en) 2020-12-03 2021-12-03 Bcma-targeted car-t cell therapy for multiple myeloma

Publications (2)

Publication Number Publication Date
JP2023551877A JP2023551877A (ja) 2023-12-13
JP2023551877A5 true JP2023551877A5 (cg-RX-API-DMAC7.html) 2024-12-12

Family

ID=79270135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533310A Pending JP2023551877A (ja) 2020-12-03 2021-12-03 Bcmaを標的とする、多発性骨髄腫のためのcar-t細胞療法

Country Status (15)

Country Link
US (3) US20220265710A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255450A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551877A (cg-RX-API-DMAC7.html)
KR (1) KR20230118556A (cg-RX-API-DMAC7.html)
CN (1) CN116888147A (cg-RX-API-DMAC7.html)
AR (1) AR124248A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021392708A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203603A1 (cg-RX-API-DMAC7.html)
IL (1) IL303312A (cg-RX-API-DMAC7.html)
JO (1) JOP20230122A1 (cg-RX-API-DMAC7.html)
MA (1) MA71426A (cg-RX-API-DMAC7.html)
MX (1) MX2023006371A (cg-RX-API-DMAC7.html)
TW (1) TW202237637A (cg-RX-API-DMAC7.html)
UY (1) UY39555A (cg-RX-API-DMAC7.html)
WO (2) WO2022116086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
AU2021266428A1 (en) * 2020-05-04 2023-01-19 Bio-Diagnostics Limited A diagnostic device
WO2024146398A1 (zh) * 2023-01-04 2024-07-11 北京艺妙神州医药科技有限公司 分离的抗体、包含该抗体的car及其用途
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
CA3205511A1 (en) * 2023-04-19 2025-03-17 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2026090579A1 (en) 2024-10-25 2026-04-30 Janssen Biotech, Inc. Methods of treating smoldering multiple myeloma with ciltacabtagene autoleucel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
PL3896091T3 (pl) * 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法

Similar Documents

Publication Publication Date Title
JP7339733B2 (ja) C3腎症を処置する方法
JP6918724B2 (ja) 急性骨髄性白血病(aml)のための新規併用治療
DE60225914T2 (de) Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
EP2278960B1 (en) Dosing regimen for a selective sip1 receptor agonist
JP2020203889A (ja) 抗体製剤
US8784812B2 (en) Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US8591892B2 (en) FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death
EA015560B1 (ru) Способ лечения вирусного гепатита
TR201819834T4 (tr) Stabilize sıvı anti-rsv antikor formülasyonları.
CN105209068A (zh) 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
JP2024540275A5 (cg-RX-API-DMAC7.html)
CN111265531A (zh) 治疗和预防移植物抗宿主病的方法
US12324840B2 (en) CD20-targeted antibody coupling pharmaceutical preparation
JP2017524024A (ja) 関節病態の治療
US20250242046A1 (en) Allogeneic hypoimmune biomimetic nanovesicle for the treatment of cancer
US20240415931A1 (en) Methods of use and administration of encapsulated cells
JP2011506436A (ja) 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP6494594B2 (ja) 樹状細胞を含有する医薬およびその製造方法
TW201039820A (en) Methods and compositions for treating hematological malignancies
EP3881856A1 (en) Pharmaceutical composition for treating aplastic anemia
RU2322238C2 (ru) Лечение ревматоидного артрита
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
EP4648772A1 (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
US20260053939A1 (en) Combination Therapy for Cancer
Voltarelli et al. Stem cell therapies for type 1 diabetes mellitus